Another US settlement for Takeda on Actos litigation, with Mylan
18 March 2010
Nancy Faigen
Please Login to read the full article.
18 March 2010
Nancy Faigen
Nancy.faigen@informausa.com
Mylan has become the third company to settle outstanding litigation with
Takeda Pharmaceutical regarding the antidiabetic Actos (pioglitazone), allowing it to market its generic version in the US on 17 August 2012, or earlier under certain circumstances. The other two generic firms that have settled...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pfizer settles US Lipitor patent suit against Dr Reddy's
- Steady erosion not dramatic plunge likely as Actos faces first generics in Japan
- Mylan suit pushes FDA to decide immediately on Ranbaxy ANDA for generic Lipitor
- Sandoz wants Novo's sole US Prandin patent ruled invalid in a long running case
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
